{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T17:44:58Z","timestamp":1789148698463,"version":"build-2803163510"},"reference-count":19,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T00:00:00Z","timestamp":1768262400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.esmoop.2026.106081","type":"journal-article","created":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T20:36:51Z","timestamp":1773261411000},"page":"106081","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Progression patterns and clinical outcomes in patients with cutaneous squamous-cell carcinoma following anti-PD-1 therapy failure"],"prefix":"10.1016","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6697-3516","authenticated-orcid":false,"given":"K.","family":"Khaddour","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-1960-3239","authenticated-orcid":false,"given":"P.","family":"Kote","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2496-7737","authenticated-orcid":false,"given":"A.","family":"Giobbie-Hurder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6173-2000","authenticated-orcid":false,"given":"I.","family":"Dryg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Goyal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.P.","family":"Guenette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5119-0401","authenticated-orcid":false,"given":"J.D.","family":"Schoenfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.N.","family":"Margalit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.B.","family":"Tishler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.M.","family":"Rettig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.K.V.","family":"Sethi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.J.","family":"Annino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.A.","family":"Goguen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Uppaluri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0042-6269","authenticated-orcid":false,"given":"M.","family":"de Simone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.A.","family":"Ran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Stevens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.H.","family":"Waldman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.S.","family":"Ruiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.V.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3877-3984","authenticated-orcid":false,"given":"A.W.","family":"Silk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.J.","family":"Hanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.esmoop.2026.106081_bib1","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1056\/NEJMoa2502449","article-title":"Adjuvant cemiplimab or placebo in high-risk cutaneous squamous-cell carcinoma","volume":"393","author":"Rischin","year":"2025","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.esmoop.2026.106081_bib2","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1200\/JCO.2012.48.5326","article-title":"Evaluation of American Joint Committee on Cancer, International Union Against Cancer, and Brigham and Women\u2019s Hospital tumor staging for cutaneous squamous cell carcinoma","volume":"32","author":"Karia","year":"2014","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2026.106081_bib3","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/jdv.17709","article-title":"Epidemiology of advanced cutaneous squamous cell carcinoma","volume":"36","author":"Dessinioti","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"10.1016\/j.esmoop.2026.106081_bib4","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1056\/NEJMoa1805131","article-title":"PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma","volume":"379","author":"Migden","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.esmoop.2026.106081_bib5","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.jaad.2024.06.108","article-title":"A phase 2 open-label study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (EMPOWER-CSCC-1): final long-term analysis of groups 1, 2, and 3, and primary analysis of fixed-dose treatment group 6","volume":"92","author":"Hughes","year":"2025","journal-title":"J Am Acad Dermatol"},{"issue":"10","key":"10.1016\/j.esmoop.2026.106081_bib6","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1016\/j.annonc.2021.07.008","article-title":"Pembrolizumab for locally advanced and recurrent\/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study): an open-label, nonrandomized, multicenter, phase II trial","volume":"32","author":"Hughes","year":"2021","journal-title":"Ann Oncol"},{"issue":"25","key":"10.1016\/j.esmoop.2026.106081_bib7","doi-asserted-by":"crossref","first-page":"2916","DOI":"10.1200\/JCO.19.03054","article-title":"Pembrolizumab monotherapy for recurrent or metastatic cutaneous squamous cell carcinoma: a single-arm phase II trial (KEYNOTE-629)","volume":"38","author":"Grob","year":"2020","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.esmoop.2026.106081_bib8","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007637","article-title":"Efficacy and safety of cosibelimab, an anti-PD-L1 antibody, in metastatic cutaneous squamous cell carcinoma","volume":"11","author":"Clingan","year":"2023","journal-title":"J Immunother Cancer"},{"issue":"12","key":"10.1016\/j.esmoop.2026.106081_bib9","doi-asserted-by":"crossref","first-page":"3180","DOI":"10.3390\/cancers15123180","article-title":"Cetuximab for immunotherapy-refractory\/ineligible cutaneous squamous cell carcinoma","volume":"15","author":"Marin-Acevedo","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.esmoop.2026.106081_bib10","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/s41525-021-00226-4","article-title":"The landscape of driver mutations in cutaneous squamous cell carcinoma","volume":"6","author":"Chang","year":"2021","journal-title":"NPJ Genom Med"},{"key":"10.1016\/j.esmoop.2026.106081_bib11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2019.03.004","article-title":"Chromosome 3q arm gain linked to immunotherapy response in advanced cutaneous squamous cell carcinoma","volume":"113","author":"Kacew","year":"2019","journal-title":"Eur J Cancer"},{"issue":"6","key":"10.1016\/j.esmoop.2026.106081_bib12","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/nm.4333","article-title":"Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients","volume":"23","author":"Zehir","year":"2017","journal-title":"Nat Med"},{"issue":"15","key":"10.1016\/j.esmoop.2026.106081_bib13","doi-asserted-by":"crossref","first-page":"4348","DOI":"10.1093\/bioinformatics\/btaa554","article-title":"CoMut: visualizing integrated molecular information with comutation plots","volume":"36","author":"Crowdis","year":"2020","journal-title":"Bioinformatics"},{"issue":"8","key":"10.1016\/j.esmoop.2026.106081_bib14","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002757","article-title":"Integrated analysis of a phase 2 study of cemiplimab in advanced cutaneous squamous cell carcinoma: extended follow-up of outcomes and quality of life analysis","volume":"9","author":"Rischin","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"7","key":"10.1016\/j.esmoop.2026.106081_bib15","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.3390\/cancers17071172","article-title":"Mutational profile of blood and tumor tissue and biomarkers of response to PD-1 inhibitors in patients with cutaneous squamous cell carcinoma","volume":"17","author":"Chang","year":"2025","journal-title":"Cancers (Basel)"},{"issue":"suppl 7","key":"10.1016\/j.esmoop.2026.106081_bib16","first-page":"S932","article-title":"838P Patterns of response progressive disease and management following PD with anti-PD-1 in patients with advanced cutaneous squamous cell carcinoma","volume":"33","author":"Mo","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2026.106081_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2025.115379","article-title":"Immunotherapy followed by cetuximab in locally advanced\/metastatic cutaneous squamous cell carcinomas: the I-TACKLE trial","volume":"220","author":"Bossi","year":"2025","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.esmoop.2026.106081_bib18","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1385094","article-title":"Case report: Increased efficacy of cetuximab after pembrolizumab failure in cutaneous squamous cell carcinoma","volume":"14","author":"Morecroft","year":"2024","journal-title":"Front Oncol"},{"issue":"21","key":"10.1016\/j.esmoop.2026.106081_bib19","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1200\/JCO-25-00759","article-title":"Phase II (Alliance A091802) randomized trial of avelumab plus cetuximab versus avelumab alone in advanced cutaneous squamous cell carcinoma","volume":"43","author":"Zandberg","year":"2025","journal-title":"J Clin Oncol"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702926000232?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702926000232?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T01:14:50Z","timestamp":1774487690000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702926000232"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":19,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S2059702926000232"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2026.106081","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Progression patterns and clinical outcomes in patients with cutaneous squamous-cell carcinoma following anti-PD-1 therapy failure","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2026.106081","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"106081"}}